BioPartnering North America--Programs from Pharma in Europe and the Middle East.
The BioPartnering North America conference, held in Vancouver, included presentations covering drug pipeline developments from both large and small pharmaceutical companies. This conference report highlights selected presentations from drug developers from Europe and the Middle East, specifically France, Spain, Denmark, Ireland, Sweden, Switzerland, Germany and Israel. Investigational drugs discussed include naproxcinod and NCX-116 (both NicOx SA), beta-amyloid (Abeta)40- and Abeta42-targeting vaccines (Araclon Biotech SI), ROSE-010 (Rose Pharma A/S), ADC-1004 (Alligator Bioscience AB), and VPM-4-001 (Vakzine Projekt Management GmbH).
Croydon
Léonie
L
Freelance Scientific Consultant, Vancouver, BC, Canada. leoniecroydon@gmail.com
D023582:Alzheimer Vaccines / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004345:Drug Industry; D015507:Drugs, Investigational / Q000627:therapeutic use*; D005060:Europe; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008877:Middle East; D020030:Nitric Oxide Donors / Q000627:therapeutic use; D016896:Treatment Outcome
D023582:Alzheimer Vaccines; D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D005765:Gastrointestinal Agents; D007155:Immunologic Factors; D020030:Nitric Oxide Donors